Application 220367
- Type
- ANDA
- Sponsor
- STERANCO HLTHCARE
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | NYSTATIN | NYSTATIN | SUSPENSION;ORAL | 100,000 UNITS/ML | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A220367-001 | NYSTATIN | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 2026-02-05 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A220367-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 2026-02-05 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A220367-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 2026-02-05 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A220367-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2026-02-05 | 011fe1cb6892… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A220367-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2026-02-05 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A220367-001 | AA | 1 | 011fe1cb6892… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A220367-001 | AA | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Nystatin | NYSTATIN | Proficient Rx LP | e7f0e152-233a-492e-a297-7bf2c543c113 | 2022-05-02 | Adverse reactions | Nystatin NYSTATIN |
| Nystatin | NYSTATIN | Pharmaceutical Associates, Inc. | 31e3da10-5a7b-4bc5-8a4f-3e786b64c13a | 2022-01-13 | Adverse reactions | Nystatin NYSTATIN |
| Nystatin | NYSTATIN | Macleods Pharmaceuticals Limited | d8ebb61a-a326-4f0d-a346-c3db045c3fb0 | 2021-08-25 | Adverse reactions | Nystatin NYSTATIN |
| nystatin | NYSTATIN | Proficient Rx LP | 04d795f3-aad7-4b79-8ebc-43c500afe39b | 2021-08-01 | Adverse reactions | nystatin NYSTATIN |
| Nystatin | NYSTATIN | Macleods Pharmaceuticals Limited | fe3db8b2-9de4-4f9e-b763-8536a1e4cea8 | 2021-01-29 | Adverse reactions | Nystatin NYSTATIN |
| Nystatin | NYSTATIN OINTMENT | Proficient Rx LP | 711950c4-1889-4acd-ab76-9a16176ce1e4 | 2020-03-01 | Adverse reactions | Nystatin |
| Nystatin | NYSTATIN | Proficient Rx LP | 5ef15e1c-66dc-4858-8552-d83e42c3883e | 2019-11-01 | Adverse reactions | Nystatin NYSTATIN |
| NYSTATIN | NYSTATIN | Leading Pharma, LLC | 8900ba02-2c6a-4dd4-b82f-45620c06e255 | 2019-09-19 | Adverse reactions | NYSTATIN NYSTATIN |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.